Subscribe to RSS
DOI: 10.1055/a-2652-7957
Lung Chemoperfusion Improves Relapse-Free Survival after Metastasectomy for Colorectal Cancer

Abstract
Introduction
Metastasectomy is a recommended and widely used operation for pulmonary metastases from colorectal cancer (CRC). The main disadvantage of pulmonary metastasectomy is the high rate of metastasis recurrence, which occurs in almost half of patients. To suppress residual pulmonary microfoci, isolated lung chemoperfusion (ILuP) is used, but its effectiveness has not been studied.
Material and Methods
The results of pulmonary metastasectomy were studied in 160 patients. In 65 patients of the main group, open metastasectomy with isolated chemoperfusion of the lungs was performed; in 95 patients of the control group, standard open or thoracoscopic metastasectomy was performed. The study design included 1:1 pseudorandomization using the nearest neighbor method. For 17 patients who underwent standard metastasectomy and then metastasectomy with ILuP for recurrent pulmonary metastases, these patients themselves were used as the nearest neighbor. For the remaining patients, the matching pairs were selected by the Propensity Score Matching method. After balancing the sample, the main and control groups comprised 41 pairs of observations, which were subjected to further analysis with assessment of relapse-free pulmonary survival according to Kaplan–Meier. Factors influencing survival were studied in the Cox's model.
Results
The median recurrence-free survival in patients of the main group who underwent metastasectomy with ILuP was 22.3 months versus 9.1 months in the control group. One-year recurrence-free survival in the main group was 77.5 ± 6.6% versus 38.1 ± 9.1% in the control group.
Conclusion
Isolated lung chemoperfusion increases median recurrence-free survival after pulmonary metastasectomy by more than one year for colorectal cancer.
Publication History
Received: 24 March 2025
Accepted: 08 July 2025
Accepted Manuscript online:
11 July 2025
Article published online:
24 July 2025
© 2025. Thieme. All rights reserved.
Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
-
References
- 1 Handy JR, Bremner RM, Crocenzi TS. et al. Expert consensus document on pulmonary metastasectomy. Ann Thorac Surg 2019; 107 (02) 631-649
- 2 Carvajal C, Facundo H, Puerto P, Carreño J, Beltrán R. Lung metastasectomy from colorectal cancer, 10-year experience in a South American Cancer Center. Front Surg 2022; 9: 913678
- 3 Forster C, Ojanguren A, Perentes JY. et al. Survival prognostic and recurrence risk factors after single pulmonary metastasectomy. J Cardiothorac Surg 2021; 16 (01) 357
- 4 Ratto GB, Toma S, Civalleri D. et al. Isolated lung perfusion with platinum in the treatment of pulmonary metastases from soft tissue sarcomas. J Thorac Cardiovasc Surg 1996; 112 (03) 614-622
- 5 Levchenko EV, Kalinin PS, Senchik KY. et al. [Immediate results of isolated chemoperfusion of the lung with melphalan and cisplatin in combination with metastasectomy in treatment for resectable metastatic lung lesions]. Vopr Onkol 2015; 61 (06) 960-964
- 6 Treasure T, Farewell V, Macbeth F. et al.; PulMiCC Trial Group. Pulmonary metastasectomy versus continued active monitoring in colorectal cancer (PulMiCC): a multicentre randomised clinical trial. Trials 2019; 20 (01) 718
- 7 Milosevic M, Edwards J, Tsang D. et al. Pulmonary metastasectomy in colorectal cancer: Updated analysis of 93 randomized patients - control survival is much better than previously assumed. Colorectal Dis 2020; 22 (10) 1314-1324
- 8 D'Agostino Jr RB. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998; 17 (19) 2265-2281
- 9 Levchenko EV, Klochkov MV, Mikhnin AE. et al. Surgical treatment of pulmonary metastases in colorectal cancer. The impact of isolated lung chemoperfusion on disease-free survival (in the lung). Vopr Onkol 2024; 70 (04) 707-716
- 10 Reeve BB, Smith AW, Arora NK, Hays RD. Reducing bias in cancer research: application of propensity score matching. Health Care Financ Rev 2008; 29 (04) 69-80